SEC FORM 3
SEC Form 3
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
| OMB APPROVAL |
| OMB Number: |
3235-0104 |
| Estimated average burden |
| hours per response: |
0.5 |
|
|
1. Name and Address of Reporting Person*
| MARKER THERAPEUTICS, INC. |
| 2450 HOLCOMBE BLVD, TMC PARTNERS OFFICE |
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 10/31/2025
|
3. Issuer Name and Ticker or Trading Symbol
Marker Therapeutics, Inc.
[ MRKR ]
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
 |
Director |
|
10% Owner |
|
Officer (give title below) |
|
Other (specify below) |
|
|
5. If Amendment, Date of Original Filed
(Month/Day/Year)
|
6. Individual or Joint/Group Filing (Check Applicable Line)
 |
Form filed by One Reporting Person |
|
Form filed by More than One Reporting Person |
|
| Table I - Non-Derivative Securities Beneficially Owned |
| 1. Title of Security (Instr.
4)
|
2.
Amount of Securities Beneficially Owned (Instr.
4)
|
3. Ownership Form: Direct (D) or Indirect (I) (Instr.
5)
|
4. Nature of Indirect Beneficial Ownership (Instr.
5)
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
| 1. Title of Derivative Security (Instr.
4)
|
2. Date Exercisable and Expiration Date
(Month/Day/Year) |
3. Title and Amount of Securities Underlying Derivative Security (Instr.
4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form: Direct (D) or Indirect (I) (Instr.
5)
|
6. Nature of Indirect Beneficial Ownership (Instr.
5)
|
| Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
| Explanation of Responses: |
| Remarks: |
| No securities are beneficially owned. |
|
/s/ Julio C. Esquivel as Attorney-In-Fact for Kathryn Penkus Corzo |
11/04/2025 |
|
** Signature of Reporting Person |
Date |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
| * If the form is filed by more than one reporting person,
see
Instruction
5
(b)(v). |
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure. |
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |
MARKER THERAPEUTICS, INC.
POWER OF ATTORNEY
(For Executing Form ID and Forms 3, 4 and 5
and Schedules 13D and 13G)
Know all by these presents, that the undersigned
hereby constitutes and appoints each of Mark A. Catchur,
Julio C. Esquivel, Francis Paschal and April Richards
of Shumaker, Loop & Kendrick, LLP, and Juan F. Vera
of Marker Therapeutics, Inc. (the Company), signing
individually, the undersigned's true and lawful
attorneys-in fact and agents to:
(1) Prepare, execute in the undersigned's name
and on the undersigned's behalf, and submit to the
Securities and Exchange Commission (the SEC) Form ID
and Forms 3, 4 and 5 (including amendments thereto
and joint filing agreements in connection therewith)
in accordance with Section 13 or Section 16 of the
Securities Exchange Act of 1934, as amended
(the Exchange Act) and the rules thereunder in the
undersigned's capacity as a beneficial owner of a
registered class of securities of the Company;
(2) Do and perform any and all acts for
and on behalf of the undersigned that may be
necessary or desirable to prepare and execute
any such Form ID and Forms 3, 4 or 5,
Schedules 13D and 13G (including amendments
thereto and joint filing agreements
in connection therewith) and Forms 144,
and file such forms with the SEC and any
stock exchange, self-regulatory association
or any similar authority; and
(3) Take any other action of any type
whatsoever in connection with the foregoing that,
in the opinion of such attorney-in-fact,
may be of benefit to, in the best interest of
, or legally required of the undersigned,
it being understood that the documents executed
by the attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney
shall be in such form and shall contain such terms
and conditions as the attorney-in-fact may approve
in the attorney-in-fact's discretion.
The undersigned hereby grants to each such
attorney in fact full power an authority to do
and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the
exercise of any of the rights and powers herein
granted, as fully to all intents and purposes as
the undersigned might or could do if personally
present, with full power of substitution or revocation,
hereby ratifying and confirming all that such
attorney in fact, or such attorney in fact's
substitute or substitutes, shall lawfully do
or cause to be done by virtue of this power of
attorney and the rights and powers herein granted.
The undersigned acknowledges that the foregoing
attorneys-in-fact, and their substitutes, in serving
in such capacity at the request of the undersigned,
are not assuming (nor is the Company assuming)
any of the undersigned's responsibilities to
comply with Sections 13 and 16 of the Exchange Act
and Rule 144 thereunder.
This Power of Attorney shall remain in full force
and effect until the earliest to occur of (a) the
undersigned is no longer required to file Form ID
or Forms 3, 4 and 5 or Schedules 13D or 13G with
respect to the undersigned's holdings of and
transactions in securities issued by the Company,
(b) revocation by the undersigned in a signed
writing delivered to the Company and the foregoing
attorneys-in fact or (c) as to any attorney-in-fact
individually, until such attorney-in-fact is no
longer employed by Shumaker, Loop & Kendrick, LLP or by the Company.
IN WITNESS WHEREOF, the undersigned has caused
this Power of Attorney to be executed as of the date written
below.
Date: October 15, 2025
By:/s/ Kathryn Penkus Corzo
Name:
Kathryn Penkus Corzo